FIND (Foundation for Innovative New Diagnostics), a Geneva-based not-for-profit, and Global BioDiagnostics Corp. (GBD), a US-based start-up biotechnology company formed to commercialize potentially breakthrough technology to diagnose tuberculosis (TB), announced a collaboration to develop a rapid, low-cost and simple test for the detection of active TB in a Point-of-Care (POC) setting.
“FIND has been extremely successful in the development of state-of-the-art molecular diagnostics for the district and sub-district level of the healthcare system over the past seven years. To complement these, we are dedicated to the development of a simple, easy-to-use, cost-effective diagnostic test for the peripheral health clinic setting,” said Dr. Giorgio Roscigno, FIND’s Chief Executive Officer. “Our collaboration with GBD will hopefully result in a practical tool that can be used by community health workers, allowing them to find TB patients earlier and closer to where they live. This partnership is in line with FIND’s mission to develop and implement innovative diagnostics to impact poverty-related diseases and to create effective technologies that respond to patient needs at all levels of the health system.” – prweb.com